Name	ONG Sin Tiong
Current Position & Affiliation	Professor, Programme in Cancer and Stem Cell Biology, Duke-NUS Medical School, and Professor, Department of Medicine, Duke University Medical Center, Durham, NC, USA.
Country	Singapore
Major Field	Chronic myeloid leukemia, biomarkers, drug resistance, drug development

Educational Background

1985 MA Cambridge University, United Kingdom.
1987 MBBCh Cambridge University School of Clinical Medicine.

Professional Experience

1. Director and Assistant Dean, MD-PhD Programme Office, Duke-NUS Medical School, Singapore.
2. Assistant Professor, Division of Hematology/oncology, University of California at Irvine, Irvine, CA, USA.
3. Fellow, Division of Hematology/oncology, University of Chicago Hospitals, Chicago, IL, USA.
4. Medical Resident, Department of Medicine, National University Hospital, Singapore.
5. House officer, Department of Medicine, Addenbrookes' Hospital, Cambridge, UK; and Milton Keynes General Hospital, Milton Keynes, UK.

Other Experience and Professional Memberships

1. American Society of Hematology
2. American Society for Clinical Investigation

Main Scientific Publications

1. Yu M, Nah GSS, Krishnan V, Sulaimi FNB, Ng KP, Wang C, Bhatt S, Chuah C, Bergstrom DE, **Ong ST**. The BIM deletion polymorphism potentiates the survival of leukemia stem and progenitor cells and impairs response to targeted therapies. Leukemia. 2025 Jan;39(1):134-143.
2. Dawson A, Zarou MM, Prasad B, Bittencourt-Silvestre J, Zerbst D, Himonas E, Hsieh Y-C, van Loon I, Blanco GR, Inniciello A, Krishnan V, Agarwal P, Almasoudi H, McCluskey L, Hopcroft LEM, Scott MT, Baquero P, Dunn K, Vetrie D, Copland M, Bhatia R, Coffelt SB, **Ong ST**, Wheadon H, Zanivan S, Kirschner K, Helgason GV. Leukaemia Exposure Alters the Transcriptional Profile and Function of BCR::ABL1 Negative Macrophages in the Bone Marrow Niche. Nature Communications. 2024 Feb 5;15(1):1090.
3. Krishnan V, Schmidt F, Nawaz Z, Venkatesh PN, Lee KL, Ren X, Chan ZE, Yu M, Makheja M, Rayan NA, Lim MGL, Cheung AMS, Bari S, Chng WJ, Than H, Ouyang J, Rackham O, Tan TZ, Hwang WYK, Chuah C, Prabhakar S, **Ong ST**. A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia.

With accompanying editorial. Blood. 2023 Jun 1;141(22):2738-2755.

4. Schmidt, F.; Ranjan, B.; Lin, Q.; Krishnan, V.; Joanito, I.; Honardoost, MA.; Nawaz, Z.; Venkatesh, P.; Tan, J.; Rayan, N.; **Ong ST**.; Prabhakar, S. RCA2: a scalable supervised clustering algorithm that reduces batch effects in scRNA-seq data. Nucleic Acids Research 2021; 49 (15):8505-8519.
5. Ko TK, Javed A, Lee KL, Pathiraja TN, Liu X, Malik S, Soh SX, Heng XT, Takahashi N, Tan JHJ, Bhatia R, Khng AJ, Chng WJ, Sia YY, Fruman DA, Ng KP, Chan ZE, Xie KJ, Hoi Q, Chan CX, Teo ASM, Velazquez Camacho O, Meah WY, Khor CC, Ong CTJ, Soon WJW, Tan P, Ng PC, Chuah C, Hillmer AM, **Ong ST**. An integrative model of pathway convergence in genetically heterogeneous blast crisis CML. Blood Plenary Paper with accompanying editorial. Blood. 2020 Jun 25;135(26):2337-2353.
6. Takeuchi S, Hase T, Shimizu S, Ando M, Hata A, Murakami H, Kawakami T, Nagase K, Yoshimura K, Fujiwara T, Tanimoto A, Nishiyama A, Arai S, Fukuda K, Katakami N, Takahashi T, Hasegawa Y, Ko TK, **Ong ST**, Yano S. Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double-positive lung cancer. Cancer Science. 2020 Feb;111(2):561-570.
7. Tanimoto, A.; Takeuchi, S.; Arai, S.; Fukuda, K.; Yamada, T.; Roca, X.; **Ong ST**.; Yano, S., Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib-resistance in EGFR-mutant lung cancer. Clinical Cancer Research 2017, 23 (12), 3139.
8. Ng KP, Manjeri A, Lee KL, Huang W, Tan SY, Chuah CT, Poellinger L, **Ong ST**. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. Blood. 2014 May 22;123(21):3316-26.
9. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JW, Allen JC, Jr., Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Chowbay B, Chang CT, Nadarajan VS, Chng WJ, Than H, Lim LC, Goh YT, Zhang S, Poh D, Tan P, Seet JE, Ang MK, Chau NM, Ng QS, Tan DS, Soda M, Isobe K, Nothen MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Tan EH, Yatabe Y, Mano H, Soo RA, Chin TM, Lim WT, Ruan Y, **Ong ST**. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. With accompanying editorial. Nature Medicine. 2012 Mar 18;18(4):521-8.
10. Janes, M. R.; Limon, J. J.; So, L.; Chen, J.; Lim, R. J.; Chavez, M. A.; Vu, C.; Lilly, M. B.; Mallya, S.; **Ong ST**.; Konopleva, M.; Martin, M. B.; Ren, P.; Liu, Y.; Rommel, C.; Fruman, D. A., Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Medicine 2010, 16 (2), 205-213.